TABLE 1.

Probability of target attainment of de-escalation antifungal treatment against Candida spp. in critically ill patients with different weights using epidemiologic cutoff values as pharmacodynamics index

Antifungal	fAUC0–24/MIC	Dosing regimena	Probability of target attainment (%) for Candida species according to wt (kg)b
			C. albicans			C. glabrata			C. parapsilosis			C. tropicalis			C. krusei
			50	75	100	50	75	100	50	75	100	50	75	100	50	75	100
Fluconazole	25	6 mg/kg QD i.v.	100	100	100	0.2	0	0	100	100	100	100	100	100
		400 mg QD i.v.		100	100		0	0		100	100		100	100
		12 mg/kg QD i.v.				100	99.9	99.8
		800 mg QD i.v.					98.3	6.6
		6 mg/kg QD p.o.	100	100	100	0	0	0	100	100	100	100	100	100
		400 mg QD p.o.		100	100		0	0		100	100		100	100
		12 mg/kg QD p.o.				0	0	0.5
		800 mg QD p.o.				38.6
Voriconazolec	25	150 mg q12h i.v.		100			100			100			100			86.9
		150 mg q12h p.o.		100			100			100			100			60.3
		200 mg q12h i.v.		100			100			100			100			99.8
		200 mg q12h p.o.		100			100			100			100			97.8

^aQD, once a day; i.v., intravenously; p.o., orally.

^bBoldface indicates PTA of ≤90%. Body weights are given as 50, 75, and 100 kg.

^cPTA values for voriconazole are calculated regardless of weight.